Associated Papers
CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation.
Phuan PW et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, 2021
Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis.
Pinto MC et al.
Journal of Experimental Pharmacology, 2021
Preclinical Studies of a Rare CF-Causing Mutation in the Second Nucleotide Binding Domain (c.3700A>G) Show Robust Functional Rescue in Primary Nasal Cultures by Novel CFTR Modulators.
Laselva O et al.
Journal of Personalized Medicine, 2020
Stabilization of a nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator yields insight into disease-causing mutations.
Vernon RM et al.
The Journal of Biological Chemistry, 2017
Facilitating Structure-Function Studies of CFTR Modulator Sites with Efficiencies in Mutagenesis and Functional Screening.
Molinski SV et al.
Journal of Biomolecular Screening, 2015
Genetic, cell biological, and clinical interrogation of the CFTR mutation c.3700 A>G (p.Ile1234Val) informs strategies for future medical intervention.
Molinski SV et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2014
Select a paper to view details